{"name":"CR-CSSS Champlain-Charles-Le Moyne","slug":"cr-csss-champlain-charles-le-moyne","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Piperacillin-tazobactam administered in a standard infusion","genericName":"Piperacillin-tazobactam administered in a standard infusion","slug":"piperacillin-tazobactam-administered-in-a-standard-infusion","indication":"Other","status":"marketed"},{"name":"Emend® (Aprepitant)","genericName":"Emend® (Aprepitant)","slug":"emend-aprepitant","indication":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Zyprexa® (OLANZapine 5MG)","genericName":"Zyprexa® (OLANZapine 5MG)","slug":"zyprexa-olanzapine-5mg","indication":"Treatment of schizophrenia","status":"phase_3"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"aflibercept + FOLFIRI","genericName":"aflibercept + FOLFIRI","slug":"aflibercept-folfiri","indication":"Metastatic colorectal cancer (in combination with FOLFIRI)","status":"marketed"}]}],"pipeline":[{"name":"Piperacillin-tazobactam administered in a standard infusion","genericName":"Piperacillin-tazobactam administered in a standard infusion","slug":"piperacillin-tazobactam-administered-in-a-standard-infusion","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Emend® (Aprepitant)","genericName":"Emend® (Aprepitant)","slug":"emend-aprepitant","phase":"phase_3","mechanism":"Aprepitant blocks substance P neurokinin-1 (NK1) receptors in the chemoreceptor trigger zone and vomiting center to prevent chemotherapy-induced nausea and vomiting.","indications":["Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy","Prevention of postoperative nausea and vomiting (PONV)"],"catalyst":""},{"name":"Zyprexa® (OLANZapine 5MG)","genericName":"Zyprexa® (OLANZapine 5MG)","slug":"zyprexa-olanzapine-5mg","phase":"phase_3","mechanism":"Zyprexa works by blocking the action of dopamine and serotonin in the brain, which helps to reduce symptoms of psychosis.","indications":["Treatment of schizophrenia","Treatment of bipolar disorder"],"catalyst":""},{"name":"aflibercept + FOLFIRI","genericName":"aflibercept + FOLFIRI","slug":"aflibercept-folfiri","phase":"marketed","mechanism":"Aflibercept blocks VEGF signaling to inhibit tumor angiogenesis, while FOLFIRI chemotherapy directly kills cancer cells through fluorouracil and irinotecan.","indications":["Metastatic colorectal cancer (in combination with FOLFIRI)","Second-line treatment of metastatic colorectal cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"marketed":2,"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}